Edwards Lifesciences Co. (NYSE:EW) Shares Sold by AdvisorNet Financial Inc

AdvisorNet Financial Inc decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 18.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,491 shares of the medical research company’s stock after selling 341 shares during the period. AdvisorNet Financial Inc’s holdings in Edwards Lifesciences were worth $110,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Peoples Bank KS purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $40,000. Finally, JFS Wealth Advisors LLC raised its position in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 over the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on EW. Truist Financial reissued a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Robert W. Baird dropped their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Piper Sandler reduced their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $69.77 on Friday. The business has a 50-day moving average of $71.99 and a two-hundred day moving average of $71.60. The firm has a market capitalization of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.